Activity Provided By:

Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

A Glimpse Into Future of Myeloma Patient Management

Overview / Abstract:	ACTIVITY DESCRIPTION In the last 18 years, oncology clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. In this time, 16 new drugs have been approved by the US Food and Drug Administration (FDA) for use in MM—including 10 in the last 6 years alone. The rapidity with which clinical data relating to MM therapy (including for smoldering multiple myeloma) continues to evolve and emerge all but ensures that the MM treatment paradigm will continue to change significantly in the future. Developed to help hematologist-oncologists prepare for advancements in MM patient management protocols, this activity features presentations on current and evolving MM patient care practices and discussions of how they are likely to evolve over the next 3 to 5 years. Educational Objectives Upon completion of this activity, participants should be better able to (1) interpret the cytogenetic, molecular, and other standard staging tests used to define risk and prognosis for patients with myeloma precursor conditions and MM; (2) distinguish between the indicated uses and mechanisms of action of current and emerging treatment regimens; (3) evaluate emerging data regarding the approach to MRD testing; (4) develop individualized management plans for MM patients based on risk and cytogenetic and genomic data
Expiration	Jan 24, 2023
Discipline(s)	Nurse Practitioner , Physician CME, Physician Assistant CME
Format	Webinar / Webcast / Video
Credits / Hours	This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Penn State College of Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation	ACCME
Presenters / Authors / Faculty	Hearn Jay Cho, MD, PhD—Program Co-Chair Chief Medical Officer Multiple Myeloma Research Foundation Norwalk, Connecticut Associate Professor of Medicine Icahn School of Medicine at Mount Sinai New York, New York Paul G. Richardson, MD—Program Co-Chair R. J. Corman Professor of Medicine Harvard Medical School Clinical Program Leader and Director of Clinical Research Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston, Massachusetts A. Keith Stewart, MBChB—Program Co-Chair Vice President, Cancer, University Health Network Medical Director, Princess Margaret Cancer Centre Regional Vice President, Toronto Central South, Ontario Health Richard H. Clark Chair in Cancer Medicine Toronto, Ontario, Canada Amrita Y. Krishnan, MD Director, Judy and Bernard Briskin Center for Multiple Myeloma Research Professor, Department of Hematology and Hematopoietic Cell Transplantation City of Hope Medical Center Duarte, California Elisabet E. Manasanch, MD Associate Professor The University of Texas MD Anderson Cancer Center Houston, Texas Nina Shah, MD Professor of Clinical Medicine Division of Hematology/Oncology University of California San Francisco San Francisco, California
Activity Specialities / Related Topics	Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy
Sponsors / Supporters / Grant Providers	Support for this activity has been provided through educational grants from AbbVie, Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Oncopeptides, and Sanofi Genzyme. The joint sponsors also wish to thank CURE and Targeted Oncology for their support.
Keywords / Search Terms	RedMedEd RedMedEd RedMedEd RedMedEd MMRF, MM, multiple myeloma, multiple myeloma research foundation, cytogenetic, molecular, tests, risk, prognosis, patients, precursor conditions, mechanisms of action, emerging treatment, options, data, MRD, MRD testing, genomic, genomic data, risk, management, evolving, care, practice, Free, CME, CE, hematologist, hematology, oncology, clinical data, therapy Free CE CME Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map